Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Incisional Recurrences After Endometrial Cancer Surgery

GIORGIO BOGANI, SEAN C. DOWDY, WILLIAM A. CLIBY, BOBBIE S. GOSTOUT, SANJEEV KUMAR, FABIO GHEZZI, FRANCESCO MULTINU and ANDREA MARIANI
Anticancer Research November 2015, 35 (11) 6097-6104;
GIORGIO BOGANI
1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEAN C. DOWDY
1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WILLIAM A. CLIBY
1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BOBBIE S. GOSTOUT
1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SANJEEV KUMAR
1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FABIO GHEZZI
2Department of Obstetrics and Gynecology, University of Insubria, Del Ponte Hospital, Varese, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCESCO MULTINU
1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREA MARIANI
1Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mariani.andrea{at}mayo.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: The aim of the present study was to estimate the incisional recurrence (IR) rate after endometrial cancer (EC) staging surgery and analyze characteristics of affected patients. Patients and Methods: We retrospectively searched for patients with EC at 2 institutions and analyzed the occurrence of IR after open, laparoscopic, or robotic surgery. Additionally, a review of the literature was performed. Results: Out of 2,636 patients with EC, 1,732 (65.7%), 461 (17.5%), and 443 (16.8%) had open, laparoscopic, and robotic surgery, respectively. Only 3 patients (0.11%) had IR, all after open surgery. Additionally, 38 cases of IR were identified from the literature. Patients with non-isolated IR had worse overall survival than patients with isolated IR (p=0.04). Among this latter group, combined treatments may be associated with improved survival outcome. Conclusion: IR after EC surgery is rare and may occur after minimally-invasive or open operations. Combination of local and systemic treatments may provide favorable outcomes for patients with isolated IR.

  • Endometrial cancer
  • incisional recurrence
  • laparoscopy
  • open surgery
  • port site metastases

Endometrial cancer (EC) is the most prevalent gynecologic cancer in developed countries (1). In 2014, the number of estimated new EC cases in the United States was more than 52,000, with an estimated 8,590 cancer-related deaths due to EC (2). The 5-year relative survival rate for cancer of the uterine corpus is more than 80%. This good prognosis is related to an early stage of diagnosis in most EC patients (1). In fact, most patients with tumor limited to the uterus at-diagnosis have a low risk of recurrence (2-15%) (3, 4). Recurrence associated with EC has 4 main routes of dissemination: vaginal (local), lymphatic (locoregional), peritoneal (distant), or hematogenous (distant) (4).

Recently, great interest has been attributed on recurrence at the site of surgical incision, because of the concern that minimally-invasive treatment can be a risk factor (5). Although many articles have been published, the real magnitude of incisional recurrence (IR) and its clinical course remain obscure (5-32). Several studies report minimally-invasive surgery as being responsible for tumor seeding into the incision (11, 33). IR at the site of the open abdominal wound, although rare, has been described since 1986 (6).

No consensus exists regarding the incidence of risk factors for and management of IR in patients with EC. Therefore, the aim of this study was to estimate the incidence of IR in a large cohort of patients undergoing open abdominal, laparoscopic, and robotically-assisted surgery for EC. Moreover, through a systematic review of the medical literature, we sought to identify characteristics of, risk factors for, and prognosis of IR.

Patients and Methods

Patients. We retrospectively searched for the medical records of consecutive women who underwent treatment for EC at 2 gynecologic oncology units (Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota, and Gynecologic Oncology Unit, University of Insubria, Varese, Italy) from January 1, 1999, through December 31, 2012. Institutional review board approval for this study was obtained from both institutions. Patients gave written consent for the use of personal records for health research.

Surgical procedures. Detailed description of surgical guidelines for both institutions are reported elsewhere (3, 34). Data concerning the type of surgical procedures, intraoperative and postoperative details, adjuvant therapy, and follow-up evaluations were prospectively recorded in the computerized oncology database of both units. Patients who had only a vaginal approach were excluded from the study; patients who had vaginal hysterectomy followed by other staging procedure (e.g., lymphadenectomy, omentectomy) via open abdominal, laparoscopic, or robotic surgery were included in the study.

Open abdominal, laparoscopic, and robotically-assisted surgical procedures have been described in detail elsewhere (34-36). Women undergoing laparoscopic staging had type IV E total laparoscopic hysterectomy (according to the American Association of Gynecologic Laparoscopists classification) (34). An intrauterine manipulator (RUMI System; Cooper Surgical, Inc. Trumbull, CT, USA) in conjunction with a Koh Cup (Koh Colpotomizer System; Cooper Surgical, Inc. Trumbull, CT, USA) was inserted (34). A CO2 pneumoperitoneum was created using a Veress needle, followed by introduction of a (3- to 10-mm) 0° operative laparoscope at the umbilical site. Three 3- to 12-mm ancillary trocars (1 suprapubic and 2 lateral to the epigastric arteries) were inserted with direct visualization in the left and right lower abdominal quadrants, respectively. The operation was then performed laparoscopically according to patient and disease characteristics (34). The laparoscopic patient group also included those who had undergone vaginal hysterectomy followed by laparoscopic procedures (e.g., pelvic and/or para-aortic lymphadenectomy), as previously described (36).

Robotically-assisted surgery was performed using the da Vinci Surgical System (Intuitive Surgical, Inc. Sunnyvale, CA, USA). A 12-mm trocar was placed through the umbilicus. A Veress needle was used per surgeon preference. Two ancillary trocars (8 mm) were introduced bilaterally in the abdomen, lateral to the midclavicular line, a few centimeters above the 12-mm trocar. An adjunctive third 8-mm trocar was introduced on the left side. Additionally, an ancillary laparoscopic assistant port (12 mm) was placed in the right upper abdominal quadrant. An Apple Vaginal Probe (AFS Medical, Teesdorf, Austria) was generally used to identify the vagina for bladder dissection and colpotomy (35). The RUMI uterine manipulator was used in selected patients, per surgeon preference (34). Intra-abdominal pressure was set at 10 to 12 mm Hg. The uterus was extracted from the vagina. If the uterus was too large for vaginal extraction, the surgical specimen was usually retrieved through a minilaparotomy incision. No power morcellators were used. All other surgical specimens (e.g., lymph nodes, omentum, spleen) were delivered vaginally. It was not our practice to morcellate surgical specimens. Trocar irrigation was performed per surgeon preference. Fascial closure was performed at the site of the 12-mm trocars, and skin incisions were sutured using resorbable stitches.

Patients were considered in the open rather than minimally-invasive group according to the intention-to-treat principle; hence, for the statistical analysis, laparoscopic and robotic operations that were converted to open surgery were included in the laparoscopic and robotic groups, respectively.

Follow-up. Follow-up evaluations were planned every 3 to 6 months for the first 3 years [according to National Comprehensive Cancer Network guidelines if the patient was at high or low risk for recurrence (37)] and annually thereafter. Follow-up visits included pelvic examination. Imaging studies were generally performed at the discretion of the treating physician, but no routine imaging studies are generally suggested. If IR was identified by physical examination, imaging studies were performed to identify other possible synchronous sites of recurrence. IR was defined as subcutaneous tumors, histologically documented, at the site of the surgical scar. The presence of other synchronous site(s) of recurrence was documented.

Systemic review. To provide greater insight on the rate of, risk factors for, and prognosis of IR, we reviewed the English-language literature. MEDLINE (PubMed) was searched for records from January 1, 1980, to August 10, 2013, using the terms “endometrial cancer,” “port site metastasis,” “incisional recurrence,” “scar relapse,” and “incision metastases,” alone or in combination. The reference lists of the articles retrieved were then checked manually to identify additional relevant references. Abstracts, letters, and comments not presenting original data were excluded. Articles reporting inadequate information about IR and those including cases that were subsequently reported in larger studies were excluded. Skin metastases at different sites of surgical scars were not considered in the present study. Since most of the investigations reporting IR were case reports, it was not possible to perform a heterogeneity test between different studies included in our review.

Statistical analysis. Statistical analysis was performed with GraphPad Prism version 6.00 for Mac (GraphPad Software Inc. La Jolla, CA, USA) and IBM-SPSS (version 20.0) for Mac. Incidence of events among the groups was analyzed for statistical significance with the Fisher's exact test. Normality testing (D'Agostino and Pearson test) was performed to determine whether data were sampled from a Gaussian distribution. Patient characteristics were compared between groups (minimally-invasive vs open; isolated vs non-isolated IR) using the Fisher's exact test for categorical variables, the 2-sample t-test for age, and the Mann-Whitney U-test for the time from primary surgery to IR. Because it is not possible to estimate incidence from case reports, the rate of IR after different surgical approaches was evaluated considering only studies reporting more than 100 patients undergoing EC surgery. Survival after IR was estimated using the Kaplan-Meier method. Patient characteristics were assessed for their association with death by fitting univariate Cox proportional hazards models, and associations were summarized using hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). All calculated p-values were 2-sided, and p<0.05 was considered statistically significant.

Results

During the 14-year study period, 2,842 patients underwent surgery for EC, out of whom 206 underwent vaginal hysterectomy and were excluded, thus leaving 2,636 patients for the analysis. Among these, 1,732 (65.7%), 461 (17.5%), and 443 (16.8%) patients underwent the open abdominal, laparoscopic, and robotic surgical approach, respectively. Out of 2,100 Mayo Clinic patients, the numbers for these procedures were 1,522 (72.5%), 135 (6.4%), and 443 (21.1%) patients with the open abdominal, laparoscopic, and robotically-assisted approach, respectively. From 1999 to 2008 at Mayo Clinic, 92% of cases used the open approach, compared to 41% from 2009 to 2012. The 536 patients at the University of Insubria had 210 open abdominal (39.2%), 326 laparoscopic (60.8%), and 0 robotically-assisted procedures.

Among all 2,636 patients, only 3 (0.11%) had IR: 2 out of 2,100 (0.10%) at Mayo Clinic and 1 out of 536 (0.19%) at the University of Insubria. All three IRs were diagnosed by physical examination. All IRs occurred after open abdominal surgery (3/1,732; 0.17%). The time from primary surgery to IR was 11, 13, and 24 months for these 3 patients. All three IRs were non-isolated: synchronous sites of recurrence were pelvis in 1 patient, inguinal lymph nodes in 1 patient, and vagina and spleen in 1 patient.

Our search for studies in the PubMed database describing IR in patients with EC surgery retrieved 28 studies reporting a total of 38 cases with IR (5-30). Overall, 41 cases (including our 3 cases) were included in the literature analysis: 17 (41%) occurred after open abdominal, 15 (37%) after laparoscopic, and 9 (22%) after robotic surgery. Table I summarizes the 41 cases. Median time to recurrence was 16.5 (range=1-166) months. Overall, 67% of patients with IR had uterine-confined disease (stage I-II), 78% had G1 and G2 tumors, and 69% had type I histology (endometrioid and adenosquamous).

The rates of IR after different surgical approaches, considering only studies reporting more than 100 patients undergoing surgery, are shown in Table II (5, 24, 26, 27, 30). The rates of IR were 0.11%, 0.20%, and 0.57% after open abdominal, laparoscopic, and robotically-assisted surgery, respectively (p=0.5).

Table III describes the differences between patients with IR after open abdominal (n=17, 41%) and minimally-invasive surgery (n=24, 59%). Patients undergoing minimally-invasive surgery were more likely to have extra-uterine disease at the time of primary diagnosis than those who underwent open surgery (p=0.01). No significant differences in age, International Federation of Gynecology and Obstetrics (FIGO) grade (G1 & G2 vs. G3), or histological sub-type (type I vs. type II) were observed. Events that may be considered as potential factors favoring the development of IR were described in 4 patients who had minimally-invasive surgery–port site hernia requiring reoperation (n=1), uterine perforation (n=2), and difficult uterine extraction (n=1) (15, 25, 28, 32); none of these events were reported for patients who underwent open surgery (p=0.13). Median (range) time from primary surgery to IR was significantly shorter after minimally-invasive surgery than open procedures [11 (1-48) months vs. 24 (6-166) months; p=0.02]. However, the route of primary surgery did not influence the proportion of surviving patients (HR=1.23; 95% CI,=0.30-5.05; p=.76) (Figure 1A).

Several factors influenced overall survival (Table IV). Patients with high-grade (FIGO grade 3) disease (HR=16.4; 95% CI=1.78-151.9; p=0.01) and non-isolated IR (HR=4.48; 95% CI=1.08-18.6; p=0.04 log-rank test, Figure 1B) had significantly worse overall survival. Overall, patients with non-isolated IR were more likely to have FIGO grade 3 EC than patients with isolated IR (Table V).

For the analysis of treatment modalities after IR, we focused on 13 of the 18 patients with isolated IR who had follow-up information after the IR (6, 9, 10, 13-16, 19, 23, 28, 29, 32). Patients undergoing combined local (i.e., surgery and/or radiotherapy) plus systemic treatments (i.e., chemotherapy and/or hormone therapy) had a lower recurrence rate (2/8, 25%) than patients undergoing local or systemic treatment as a single modality (4/5, 80%), although the difference did not reach statistical significance (odds ratio, 12.0; 95% CI=0.79-181.1; p=0.10). In addition, none of the 8 patients receiving a combined approach died of disease, compared to 2 of 5 patients (40%) receiving single-modality treatment (HR=9.0; 95% CI=0.55-146.7; p=0.12 log-rank test). Of note, no significant differences in measurable variables (i.e., constitutional and disease characteristics) existed between patients undergoing different therapies.

Discussion

The current study reports a low rate of IR (0.11%) in a large series of patients with EC undergoing open abdominal, laparoscopic, and robotically-assisted surgery. Moreover, analysis of the data available in the literature shows that the route of primary surgery (i.e., minimally-invasive vs. open surgery) did not affect the rate of IR or significantly influence survival. Isolated IR generally occurred in patients with FIGO grade 1 or 2 tumors. Patients with isolated IR had a better prognosis than those with other associated synchronous recurrences. Among patients with isolated IR, the use of aggressive treatments (local plus systemic therapy) seemed to provide a more favorable prognosis.

In the medical literature, data on IR in EC are limited. The few studies published on this issue show great heterogeneity among reported cases (5-32). Because of the rarity of IR, several biological and clinical features remain obscure. Multiple hypotheses have been proposed about the etiology of IR, such as spread of neoplastic cells through the lymphatic and blood vessels, implantation during surgical management (e.g., contact of the instruments with the skin), seeding of neoplastic cells through the cervical canal or the fallopian tubes, the “chimney effect” due to the aerosolization of neoplastic cells during minimally-invasive surgery, or peritoneal immunologic reactions related to CO2 (6-33, 38, 39). DerHagopian et al. (40) proposed the alternative theory of “inflammatory oncotaxis”: implantation and growth outside the primary origin site are fostered by incisional repair mechanisms such as immunohistochemical and angiogenic processes. Therefore, according to this theory, manifestation of cancer at the abdominal wall, after surgery, should not always be considered the effect of iatrogenic spread (40).

During the past decade, some reports have stressed that IR is a complication of minimally-invasive surgery (11, 38). Because of the relatively small numbers and the inherent biases of retrospective reviews of the literature, we cannot clearly determine whether the route of surgery influences the risk of IR. We emphasize, however, that IR can occur after both minimally-invasive and open abdominal surgery. Furthermore, we speculate that the rate of IR is probably under-reported, especially during open surgery. Hence, it is not possible to ascertain with adequate precision the true incidence of IR. Most of the available studies are case reports (6-10, 13-23, 25).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

IR after open abdominal and minimally-invasive endometrial cancer surgery.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Cohort studies with >100 cases reporting rate of IR after endometrial cancer surgery.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Comparison of IR after minimally-invasive (laparoscopic or robotic) vs. open abdominal surgery (n=41)a.

To the best of our knowledge, this is the first study to report the rate of IR after open surgery. Therefore, no comparison can be done with other studies. In contrast, the absence of port site IR in our series is corroborated by other investigations in the field of minimally-invasive surgery (34-36).

Unfortunately, the available information about IR is not consistent. In the largest published prospective study of minimally-invasive surgery in EC (the LAP2 study), Walker et al. (27) reported 4 cases of IR (0.24%). The authors reported that “the four abdominal wall recurrences were potentially trocar recurrence sites, because all were identified in patients undergoing laparoscopy,” whereas no cases of IR after open abdominal staging were reported (27). Additionally, among studies reporting IR after robotically-assisted surgery, detailed information on the clinical characteristics of patients with recurrence was missing in 5 of the 9 patients described (30).

We highlight 3 points of our study. First, although our data suggest that the route of primary surgery did not influence survival outcomes after IR, the interval between surgery and IR was shorter in the minimally-invasive group. It is possible that IR is more likely to be diagnosed and reported after minimally-invasive surgery than after open abdominal surgery, or the more aggressive nature of the tumor in the minimally-invasive group, compared to the open-abdominal group (53% vs. 12% had extrauterine disease at the time of primary EC diagnosis; Table III) may account for the earlier presentation of port site metastases. Second, the worse prognosis of patients with non-isolated IR probably reflects the poor outcome of patients with lymphatic, peritoneal, or hematogenous recurrence. Due to the small sample size and the heterogeneity of the studies in the literature, it is difficult to determine the efficacy of different treatments. However, on the basis of the limited data available, a combination of local (i.e., wide local excision and adjuvant radiotherapy) and systemic (chemotherapy or hormonal therapy) treatments for isolated IR seems to represent a reasonable therapeutic option (32). In contrast, therapy for non-isolated IR should be tailored on the basis of the associated synchronous site of recurrence and patients' characteristics, but the prognosis is generally poor.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Factors, at the time of primary surgery, influencing overall survival in patients with endometrial cancer and incisional recurrence.

We acknowledge certain limitations in our investigation. First, owing to the retrospective study design, the limited clinical information available from the literature, and rarity of the event, the present study is not powered to ascertain risk factors for IR after different surgical approaches (i.e., minimally-invasive vs. open abdominal surgery). Second, our review is subject to publication bias (e.g., because IR could be considered an iatrogenic complication, surgeons could be reluctant to publish series with a high rate of IR) and temporal bias (e.g., it is possible that some IR occurred after the publication of the current article). Third, because minimally-invasive surgery was introduced in the most recent decade of our study, patients undergoing procedures via open abdominal surgery had longer follow-up time than patients undergoing minimally-invasive procedures. However, most IRs occurred during a relative short follow-up period. Fourth, the lack of standardization and details about surgeries and the different treatment methods (e.g., adjuvant therapy administration) are also limitations. Nevertheless, the main strengths of the current study are represented by the large series of consecutive patients undergoing surgery for EC and the systematic review of the largest series of IR available to date in the medical literature.

In conclusion, IR is a rare event after EC surgery. Scar implantation of cancer cells is possible in both minimally-invasive and traditional open abdominal surgery. IR is usually characterized by poor prognosis when associated with other distant sites of synchronous recurrence. In contrast, isolated IR is generally observed in patients with FIGO grade 1 to 2 cancers and portends a more favorable outcome, especially when a combination of local and systemic treatments is used.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan-Meier curves showing survival outcomes after incisional recurrence (IR). A, Overall survival after incisional recurrence in patients undergoing open abdominal (n=13) vs. minimally-invasive (n=9) surgery (p=0.76, log-rank test). B, Overall survival after isolated (n=13) vs. non-isolated (n=9) IR (p=0.04, log-rank test).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Comparison of isolated vs. non-isolated IR (n=35)a.

Acknowledgements

No funding source supported this investigation.

Footnotes

  • Conflicts of Interest

    All Authors declare that there are no conflicts of interest associated with this work.

  • Received June 18, 2015.
  • Revision received August 7, 2015.
  • Accepted August 19, 2015.
  • Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Siegel R,
    2. DeSantis C,
    3. Virgo K,
    4. Stein K,
    5. Mariotto A,
    6. Smith T,
    7. Cooper D,
    8. Gansler T,
    9. Lerro C,
    10. Fedewa S,
    11. Lin C,
    12. Leach C,
    13. Cannady RS,
    14. Cho H,
    15. Scoppa S,
    16. Hachey M,
    17. Kirch R,
    18. Jemal A,
    19. Ward E
    : Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4): 220-241, 2012 Epub 2012 Jun 14. Erratum in: CA Cancer J Clin 62(5): 348, 2012.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Siegel R,
    2. Ma J,
    3. Zou Z,
    4. Jemal A
    : Cancer statistics, 2014. CA Cancer J Clin 64(1): 9-29, 2014.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bogani G,
    2. Dowdy SC,
    3. Cliby WA,
    4. Ghezzi F,
    5. Rossetti D,
    6. Mariani A
    : Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 40(2): 301-311, 2014.
    OpenUrlPubMed
  4. ↵
    1. Mariani A,
    2. Dowdy SC,
    3. Keeney GL,
    4. Long HJ,
    5. Lesnick TG,
    6. Podratz KC
    : High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 95(1): 120-126, 2004.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Martinez A,
    2. Querleu D,
    3. Leblanc E,
    4. Narducci F,
    5. Ferron G
    : Low incidence of port-site metastases after laparoscopic staging of uterine cancer. Gynecol Oncol 118(2): 145-150, 2010
    OpenUrlPubMed
  6. ↵
    1. Barter JF,
    2. Hatch KD,
    3. Orr JW Jr.,
    4. Shingleton HM
    : Isolated abdominal wound recurrence of an endometrial adenocarcinoma confined to a polyp. Gynecol Oncol 25(3): 372-375, 1986.
    OpenUrlPubMed
    1. Chapman GW Jr.,
    2. Fabacher P,
    3. Thompson H
    : Incisional recurrence of endometrial adenocarcinoma. J Natl Med Assoc 80(3): 350-351, 1988.
    OpenUrlPubMed
    1. Espinos JJ,
    2. Garcia-Patos V,
    3. Guiu XM,
    4. Delgado E
    : Early skin metastasis of endometrial adenocarcinoma: case report and review of the literature. Cutis 52(2): 109-111, 1993.
    OpenUrlPubMed
    1. Curtis MG,
    2. Hopkins MP,
    3. Cross B,
    4. Tantri MD,
    5. Jenison EL,
    6. Rehmus E
    : Wound seeding associated with endometrial cancer. Gynecol Oncol 52(3): 413-415, 1994.
    OpenUrlPubMed
  7. ↵
    1. Kotwall CA,
    2. Kirkbride P,
    3. Zerafa AE,
    4. Murray D
    : Endometrial cancer and abdominal wound recurrence. Gynecol Oncol 53(3): 357-360, 1994.
    OpenUrlPubMed
  8. ↵
    1. Kadar N
    . Port-site recurrences following laparoscopic operations for gynaecological malignancies: Br J Obstet Gynaecol 104(11): 1308-1313, 1997.
    OpenUrlPubMed
    1. Wang PH,
    2. Yen MS,
    3. Yuan CC,
    4. Chao KC,
    5. Ng HT,
    6. Lee WL,
    7. Chao HT
    : Port site metastasis after laparoscopic-assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and prevention. Gynecol Oncol 66(1): 151-155, 1997.
    OpenUrlPubMed
  9. ↵
    1. Khalil AM,
    2. Chammas MF,
    3. Kaspar HJ,
    4. Shamseddine AI,
    5. Seoud MA
    : Case report: endometrial cancer implanting in the laparotomy scar. Eur J Gynaecol Oncol 19(4): 408-409, 1998.
    OpenUrlPubMed
    1. Muntz HG,
    2. Goff BA,
    3. Madsen BL,
    4. Yon JL
    : Port-site recurrence after laparoscopic surgery for endometrial carcinoma. Obstet Gynecol 93(5 Pt 2): 807-809, 1999.
    OpenUrlPubMed
  10. ↵
    1. Faught W,
    2. Fung Kee Fung M
    : Port site recurrences following laparoscopically managed early stage endometrial cancer. Int J Gynecol Cancer 9(3): 256-258, 1999.
    OpenUrlPubMed
    1. Macias V,
    2. Baiotto B,
    3. Pardo J,
    4. Munoz F,
    5. Gabriele P
    : Laparotomy wound recurrence of endometrial carcinoma. Gynecol Oncol 91(2): 429-434, 2003.
    OpenUrlPubMed
    1. Joshi SC,
    2. Sharma DN,
    3. Khurana N,
    4. Mohanta PK,
    5. Bahadur AK
    : Endometrial carcinoma with recurrence in the incisional scar: a case report. Int J Gynecol Cancer 13(6): 901-903, 2003.
    OpenUrlPubMed
    1. Lorenz U,
    2. Gassel AM,
    3. Thiede A,
    4. Gassel HJ
    : Endometrial carcinoma recurrence in an abdominal scar 14 years after total hysterectomy. Gynecol Oncol 95(2): 393-395, 2004.
    OpenUrlCrossRefPubMed
    1. Chen CC,
    2. Straughn JM Jr.,
    3. Kilgore LC
    : Early abdominal incision recurrence in a patient with stage I adenocarcinoma of the endometrium. Obstet Gynecol 104(5 Pt 2): 1170-1172, 2004.
    OpenUrlCrossRefPubMed
    1. Baydar M,
    2. Dikilitas M,
    3. Sevinc A,
    4. Senel S,
    5. Senel F,
    6. Aydogdu I
    : Cutaneous metastasis of endometrial carcinoma with hemorrhagic nodules and papules. Eur J Gynaecol Oncol 26(4): 464-465, 2005.
    OpenUrlPubMed
    1. Sanjuán A,
    2. Hernández S,
    3. Pahisa J,
    4. Ayuso JR,
    5. Torné A,
    6. Martínez Román S,
    7. Lejárcegui JA,
    8. Ordi J,
    9. Vanrell JA
    : Port-site metastasis after laparoscopic surgery for endometrial carcinoma: two case reports. Gynecol Oncol 96(2): 539-542, 2005.
    OpenUrlPubMed
    1. Gucer F,
    2. Oz-Puyan F,
    3. Yilmaz O,
    4. Mulayim N,
    5. Balkanli-Kaplan P,
    6. Yuce MA
    : Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin. Int J Gynecol Cancer 15(6): 1195-1198, 2005.
    OpenUrlPubMed
  11. ↵
    1. Balbi GC,
    2. Cardone A,
    3. Monteverde A,
    4. Passaro M,
    5. Montone L,
    6. Rossiello R,
    7. Visconti S,
    8. Battista M,
    9. Cassese E,
    10. Landino I
    : Double laparotomy wound recurrence of endometrial carcinoma. Eur J Gynaecol Oncol 27(3): 307-309, 2006. Erratum in: Eur J Gynaecol Oncol 27(4): 320, 2006.
    OpenUrlPubMed
  12. ↵
    1. Zivanovic O,
    2. Sonoda Y,
    3. Diaz JP,
    4. Levine DA,
    5. Brown CL,
    6. Chi DS,
    7. Barakat RR,
    8. Abu-Rustum NR
    :The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol 111(3): 431-437, 2008
    OpenUrlPubMed
  13. ↵
    1. Maenpaa JU,
    2. Nyberg R,
    3. Parkkinen J
    : Port-site metastasis following laparoscopic hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 143(1): 61-62, 2009.
    OpenUrlPubMed
  14. ↵
    1. Ndofor BT,
    2. Soliman PT,
    3. Schmeler KM,
    4. Nick AM,
    5. Frumovitz M,
    6. Ramirez PT
    : Rate of port-site metastasis is uncommon in patients undergoing robotic surgery for gynecological malignancies. Int J Gynecol Cancer 21(5): 936-940, 2011.
    OpenUrlPubMed
  15. ↵
    1. Walker JL,
    2. Piedmonte MR,
    3. Spirtos NM,
    4. Eisenkop SM,
    5. Schlaerth JB,
    6. Mannel RS,
    7. Barakat R,
    8. Pearl ML,
    9. Sharma SK
    : Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30(7): 695-700, 2012. Erratum in: J Clin Oncol 30(13): 1570, 2012.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Palomba S,
    2. Falbo A,
    3. Russo T,
    4. La Sala GB
    : Port-site metastasis after laparoscopic surgical staging of endometrial cancer: a systematic review of the published and unpublished data. J Minim Invasive Gynecol 19(4): 531-537, 2012.
    OpenUrlPubMed
    1. Santeufemia DA,
    2. Lumachi F,
    3. Basso SM,
    4. Tumolo S,
    5. Re GL,
    6. Capobianco G,
    7. Bertozzi S,
    8. Pasqual EM
    : Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy as salvage treatment for a late wound recurrence of endometrial cancer. Anticancer Res 33(3): 1041-1044, 2013.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Kilgore JE,
    2. Jackson AL,
    3. Ko EM,
    4. Soper JT,
    5. Van Le L,
    6. Gehrig PA,
    7. Boggess JF
    : Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma. Gynecol Oncol 129(1): 49-53, 2013.
    OpenUrlCrossRefPubMed
    1. Nguyen ML,
    2. Friedman J,
    3. Pradhan TS,
    4. Pua TL,
    5. Tedjarati SS
    : Abdominal wall port site metastasis after robotically staged endometrial carcinoma: a case report. Int J Surg Case Rep 4(7): 613-615, 2013.
    OpenUrlPubMed
  18. ↵
    1. Grabosch S,
    2. Xynos F
    : Isolated port-site metastasis after robotic hysterectomy for stage IA endometrial adenocarcinoma. Obstet Gynecol 122(2 Pt2): 437-439, 2013.
    OpenUrlPubMed
  19. ↵
    1. Ramirez PT,
    2. Wolf JK,
    3. Levenback C
    : Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol 91(1): 179-189, 2003.
    OpenUrlPubMed
  20. ↵
    1. Bogani G,
    2. Cromi A,
    3. Uccella S,
    4. Serati M,
    5. Casarin J,
    6. Mariani A,
    7. Ghezzi F
    : Laparoscopic staging in women older than 75 years with early-stage endometrial cancer: comparison with open surgical operation. Menopause 21(9): 945-951, 2014.
    OpenUrlPubMed
  21. ↵
    1. Ramirez PT,
    2. Adams S,
    3. Boggess JF,
    4. Burke WM,
    5. Frumovitz MM,
    6. Gardner GJ,
    7. Havrilesky LJ,
    8. Holloway R,
    9. Lowe MP,
    10. Magrina JF,
    11. Moore DH,
    12. Soliman PT,
    13. Yap S
    : Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force. Gynecol Oncol 124(2): 180-184, 2012.
    OpenUrlPubMed
  22. ↵
    1. Dowdy SC,
    2. Aletti G,
    3. Cliby WA,
    4. Podratz KC,
    5. Mariani A
    : Extra-peritoneal laparoscopic para-aortic lymphadenectomy-a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol 111(3): 418-424, 2008.
    OpenUrlPubMed
  23. ↵
    1. National Comprehensive Cancer Network (NCCN) [Internet]
    . Fort Washington (PA): c2014 [cited 2015 Feb 12]. Available from: www.nccn.org.
  24. ↵
    1. Ramirez PT,
    2. Frumovitz M,
    3. Wolf JK,
    4. Levenback C
    : Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer 14(6): 1070-1077, 2004.
    OpenUrlCrossRefPubMed
    1. Watson DI,
    2. Mathew G,
    3. Ellis T,
    4. Baigrie CF,
    5. Rofe AM,
    6. Jamieson GG
    : Gasless laparoscopy may reduce the risk of port-site metastases following laparascopic tumor surgery. Arch Surg 132(2): 166-168, 1997.
    OpenUrlCrossRefPubMed
  25. ↵
    1. DerHagopian RP,
    2. Sugarbaker EV,
    3. Ketcham A
    : Inflammatory oncotaxis. JAMA 240(4): 374-375, 1978.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 35, Issue 11
November 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Incisional Recurrences After Endometrial Cancer Surgery
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Incisional Recurrences After Endometrial Cancer Surgery
GIORGIO BOGANI, SEAN C. DOWDY, WILLIAM A. CLIBY, BOBBIE S. GOSTOUT, SANJEEV KUMAR, FABIO GHEZZI, FRANCESCO MULTINU, ANDREA MARIANI
Anticancer Research Nov 2015, 35 (11) 6097-6104;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Incisional Recurrences After Endometrial Cancer Surgery
GIORGIO BOGANI, SEAN C. DOWDY, WILLIAM A. CLIBY, BOBBIE S. GOSTOUT, SANJEEV KUMAR, FABIO GHEZZI, FRANCESCO MULTINU, ANDREA MARIANI
Anticancer Research Nov 2015, 35 (11) 6097-6104;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: A Single-institutional Real-world Study
  • Cytoreductive Surgery With or Without Intraperitoneal Chemotherapy for Peritoneal Spread from Appendiceal Neoplasms and Cancers
  • Feasibility of Minimally Invasive Surgery for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy: A Four-arm Comparative Study
Show more Clinical Studies

Keywords

  • Endometrial cancer
  • incisional recurrence
  • laparoscopy
  • open surgery
  • port site metastases
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire